HIV Viral Suppression With Unintentional Lenacapavir Monotherapy in Adherence-Challenged Patients: A Case Series
Open Access
- 31 May 2025
- journal article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (6) , ofaf330
Abstract
Lenacapavir, a long-acting human immunodeficiency virus (HIV) capsid inhibitor, is thought to have a low resistance barrier based on current, limited data. We describe 4 patients experiencing homelessness with severe mental illness who maintained HIV suppression (<30 copies/mL) despite unintentional receipt of lenacapavir monotherapy for 9–38 weeks, highlighting its potential among adherence-challenged populations.Keywords
Funding Information
- National Center for Advancing Translational Sciences (2KL2TR001870)
- National Institute of Allergy and Infectious Diseases (5R37AI098472)
This publication has 11 references indexed in Scilit:
- HIV Viral Suppression With Use of Long-Acting Antiretroviral Therapy in People With and Without Initial ViremiaJAMA, 2025
- Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 YearsThe Journal of Infectious Diseases, 2025
- Virologic Failure and Emergent Integrase Strand Transfer Inhibitor Drug Resistance With Long-Acting Cabotegravir for HIV Treatment: A Meta-analysisClinical Infectious Diseases, 2024
- Viral Suppression Rates at 48 Weeks in People With HIV Starting Long-Acting Cabotegravir/Rilpivirine With Initial ViremiaClinical Infectious Diseases, 2024
- Feasibility of Implementing a Low-Barrier Long-Acting Injectable Antiretroviral Program for HIV Treatment and Prevention for People Experiencing HomelessnessJAIDS Journal of Acquired Immune Deficiency Syndromes, 2024
- Case Series of People With HIV on the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a TrialOpen Forum Infectious Diseases, 2024
- Updated Treatment Recommendation on Use of Cabotegravir and Rilpivirine for People With HIV From the IAS-USA Guidelines PanelJAMA, 2024
- Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in SwitzerlandThe Lancet Regional Health - Europe, 2023
- Demonstration Project of Long-Acting Antiretroviral Therapy in a Diverse Population of People With HIVAnnals of Internal Medicine, 2023
- Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 InfectionNew England Journal of Medicine, 2022